Bilateral injections of moxonidine, an α 2 -adrenoceptor and imidazoline receptor agonist, into the lateral parabrachial nuclei (LPBN) enhance sodium appetite induced by extracellular dehydration. In the present study, we examined whether LPBN moxonidine treatments change taste reactivity to hypertonic NaCl solution administered into the mouth by intra-oral (IO) cannula. Male Holtzman rats prepared with IO and bilateral LPBN cannulas received subcutaneous injections of furosemide (FURO; 10 mg/kg) and captopril (CAP; 5 mg/kg) to induce hypovolemia with mild hypotension and an accompanying salt appetite and thirst before testing the taste reactivity to oral infusions of 0.3 M NaCl (1.0 ml/min). In the first experiment 45 min after subcutaneous injections of FURO + CAP or vehicle, moxonidine was bilaterally injected into the LPBN, and then 15 min later both bodily and oral-facial ingestive and rejection responses to 0.3 M NaCl delivered through the IO cannula were assessed. Both LPBN vehicle and moxonidine treated rats showed increased ingestive and decreased rejection responses to the IO hypertonic solution. The IO 0.3 M NaCl infusion-evoked ingestive and rejection taste related behaviors were comparable in the LPBN vehicle-vs. the LPBN moxonidine-injected groups. In a second experiment, rats received the same FURO + CAP treatments and LPBN injections. However, beginning 15 min after the LPBN injections, they were given access to water and 0.3 M NaCl and were allowed to consume the fluids for most of the next 60 min with the free access intake being interrupted only for a few minutes at 15, 30 and 60 min after the fluids became available. During each of these three brief periods, a taste reactivity test was conducted. On the three taste reactivity tests rats that received LPBN vehicle injections showed progressive declines in ingestive responses and gradual increases in rejection responses. However, in contrast to the LPBN vehicle treated rats, animals receiving bilateral injections of LPBN moxonidine maintained a high number of ingestive responses and a low number of rejection responses throughout the test period even in spite of evidencing substantial water and 0.3 M NaCl consumption during the periods of free access. The results suggest that after α 2 -adrenoceptor agonist delivery to the LPBN the acceptance of 0.3 M NaCl is sustained and the negative attributes of the solution are minimized. The maintained positive rewarding qualities of 0.3 M NaCl are likely to account for why LPBN moxonidine treated rats show such a remarkable salt appetite when assayed by the volume of hypertonic 0.3 M NaCl consumed.
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Introduction
Sodium chloride (NaCl) is an important constituent of the extracellular fluid compartment and the major determinant of plasma osmolality and extracellular fluid volume. The acquisition and ingestion of water and of salty substances are necessary behavioral responses for an animal to recover from deficits in body fluids. Sodium deficiency results in behaviors collectively known as sodium appetite (a.k.a. salt appetite) and which can be operationally defined by an increased ingestion of sodium solutions of concentrations which are normally avoided [1] [2] [3] .
In the hindbrain, important inhibitory mechanisms for the control of water and NaCl intake have been demonstrated in the lateral parabrachial nucleus (LPBN) [4] [5] [6] [7] [8] [9] [10] . The LPBN, a pontine structure that lies dorsolateral to the superior cerebellar peduncle, is reciprocally connected to forebrain areas that have been implicated in the maintenance of blood pressure and body fluid homeostasis, such as the paraventricular nucleus of the hypothalamus, the central nucleus of the amygdala and the median preoptic nucleus. The LPBN is also richly interconnected with medullary regions, which include the area postrema (AP) and the medial portion of the nucleus of the solitary tract (mNTS), [11] [12] [13] [14] [15] [16] [17] [18] . Cells in the LPBN are activated after ingestion of sodium solutions by dehydrated rats or in rats that received intragastric loads of hypertonic NaCl [19] [20] [21] , suggesting that the LPBN might receive inhibitory visceral or taste signals. Therefore, the LPBN may integrate and relay taste and visceral signals that ascend from AP/mNTS en route to forebrain areas involved in the control of fluid and electrolyte balance [7] [8] [9] 22, 23] .
The inhibitory mechanisms of the LPBN are modulated by different neurotransmitters like serotonin, cholecystokinin, glutamate, corticotrophin releasing factor, opioids and noradrenaline [7] [8] [9] [10] [24] [25] [26] [27] [28] [29] [30] [31] [32] . Activation of α 2 -adrenoceptors with bilateral LPBN injections of moxonidine (α 2 -adrenoceptor/imidazoline receptor agonist) or noradrenaline strongly enhances 0.3 M NaCl intake induced by subcutaneous treatment with the diuretic furosemide (FURO) when combined with a low dose of the antihypertensive drug, captopril (CAP) [24, 32, 33] . This suggests that activation of α 2 -adrenoceptors in the LPBN may reduce the effects of inhibitory mechanisms that limit sodium intake [24, 32, 33] . The effects of α 2 -adrenoceptor agonist treatment of the LPBN on sodium intake are not due to a non-specific facilitation of all ingestive behaviors, because sucrose solution intake is not affected by bilateral LPBN injections of moxonidine [33] .
A taste reactivity test determining the frequency of ingestive and rejection behavioral reactions or fixed action patterns in response to intra-orally delivered solutions was originally developed by Grill and Norgren [34] . This method assesses the occurrences of species-typical affective behavioral reactions [such as ingestive-related tongue protrusions or negative (rejection) gapes] in response to oral stimulation [34, 35] . Lesions placed within either the NTS, parabrachial nucleus (PBN), or the parvocellular ventral posteromedial thalamic nucleus (VPMpc) disrupt the shift in taste reactivity observed in intact animals after sodium deficiency [36] . Lesions placed in the NTS and PBN, but not the VPMpc, also block increases in home-cage intake observed in intact, sodium deficient rats [36] .
Since α 2 -adrenoceptor activation with the administration of moxonidine into the LPBN greatly increases NaCl intake in free access intake tests, the present studies tested whether LPBN α 2 -adrenoceptor stimulation modifies taste reactivity responses to 0.3 M NaCl in rats with an experimentally-induced sodium appetite. The results of the experiments indicate that before animals ingest 0.3 M NaCl and water, LPBN moxonidine treatment does not increase or decrease the number of ingestive or rejection behaviors in comparison to those seen in LPBN vehicle treated rats. However, the findings do demonstrate that unlike LPBN vehicle treated animals showing decreased ingestive and increased rejection responses over the course of restoring body sodium and water, rats receiving LPBN moxonidine maintain a high level ingestive responses and a low number of rejection responses throughout a period of fluid repletion.
Material and methods

Animals
Male Holtzman rats weighing 290 to 310 g were housed in individual stainless steel cages with free access to normal sodium (0.5-1.0%) diet (Guabi Rat Chow, Paulínia, SP, Brazil), water and 0.3 M NaCl solution. Temperature was maintained at 23 ± 2°C, and humidity was maintained at 55 ± 10% on a 12:12 light-dark cycle with light onset at 7:30 AM. The Ethical Committee for Animal Care and Use from the Dentistry School of Araraquara -UNESP approved the experimental protocols used in the present study (protocol 06/2006). The experimental protocols also followed the U.S. National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH publication no. 80-23, 1996).
Cerebral and IO cannulas
Rats were anesthetized with ketamine (80 mg/kg of body weight) combined with xylazine (7 mg/kg of body weight) and placed in a Kopf stereotaxic instrument. The skull was leveled between bregma and lambda. Stainless steel 23-gauge cannulas were implanted bilaterally above the LPBN using the following coordinates: 9.4 mm caudal to bregma, 2.1 mm lateral to the midline, and 4.2 mm below the dura mater, according to Paxinos and Watson [37] . The tips of the cannulas were positioned at a point 2 mm above each LPBN. The cannulas were fixed to the cranium using dental acrylic resin and jeweler screws, and 20-gauge metal obturators were used to fill the cannulas between tests. Immediately after the implantation of LPBN cannulas, all animals were also implanted with chronic IO cannulas. Each oral cannula (heat-flared PE 50 tubing) entered the mouth just lateral to the first maxillary molar. The tubing was tunneled subcutaneously to ascend lateral to the skull, and posterior to the nape of neck where the free end was exteriorized. The IO cannulas do not interfere with the normal eating behavior of the animal and allow the direct infusion of solutions into the mouth. The rats were allowed to recover for 6 days before drug injections were made into the LPBN.
Injections into the LPBN
Bilateral injections into the LPBN were made using 5-μl Hamilton syringes connected by polyethylene tubing (PE-10) to 30-gauge injection cannulas. At time of testing, obturators were removed and the injection needle (2 mm longer than the guide cannulas) was introduced in the brain. All the injections into the LPBN were 0.2 μl for each site and performed over a period of 1 min, with 1 additional min allowed to elapse before the injection needle was removed from the guide cannula to avoid reflux. The movement of an air bubble inside the polyethylene tubing connected to the syringe confirmed drug flow. The obturators were replaced after injection, and the rats were placed back into the cage.
Drugs
Moxonidine hydrochloride (0.5 nmol/0.2 μl) (Solvay Pharma, Hannover, Germany) dissolved in a mix of propylene glycol and water 2:1 (vehicle) was injected into the LPBN. Vehicle was injected as control.
The natriuretic/diuretic drug FURO (10 mg/ml; Sigma Chem., St Louis, MO, USA) was dissolved in alkaline saline (0.9% NaCl, pH was adjusted to 9.0 with NaOH) and administered s.c. at the dose of 10 mg/kg of body weight. The angiotensin converting enzyme inhibitor CAP (5 mg/ml; Sigma Chem., St. Louis, MO, USA) was dissolved in saline (0.9% NaCl) and administered s.c. at the dose of 5 mg/kg of body weight. The pH 9.0 saline solution was used as the vehicle control for FURO and normal 0.9% saline as the vehicle control for CAP.
Taste reactivity test
Prior to the testing period, rats with LPBN and IO cannulas were each given a 3-day habituation period during which they were exposed to the taste reactivity chamber for 10 min, followed by a 1 ml infusion of water. Testing began 6 days after surgery, with a 48-hour interval between tests.
2.5.1. Experiment 1 -taste reactivity to 0.3 M NaCl in rats treated with sc FURO + CAP On each test day, each rat was treated with sc FURO (10 mg/kg of body weight) + CAP (5 mg/kg of body weight) or vehicle + saline. At this time, water, food and 0.3 M NaCl were removed from the rat's home cage. Forty-five minutes later, rats received bilateral injections of moxonidine (0.5 nmol/0.2 μl) or vehicle (0.2 μl) into the LPBN. Immediately after the LPBN injections, the rat's oral cannula was connected to a stimulus delivery tube, consisting of PE 50 tubing attached to an infusion pump. The rats were then placed in a cylindrical plexiglas test chamber (30 cm diameter). Fifteen minutes later (i.e., 1 h after FURO + CAP sc and 15 min after LPBN injections), 0.3 M NaCl was infused into the mouth of the animal at a constant rate (1.0 ml/min) for 1 min. The rats were given four tests. For each test the rats were divided into two groups and each group received one of the following treatments: 1) vehicle+saline (sc)+vehicle (LPBN), 2) vehicle+saline (sc) +moxonidine (LPBN), 3) FURO+CAP (sc)+vehicle (LPBN), and 4) FURO+CAP (sc)+moxonidine (LPBN). The sequence of the treatments in each group was balanced, and by the end of experiments, all animals had received all four treatments. During testing, rats had no access to water, 0.3 M NaCl and food. On each test day, each rat received FURO (10 mg/kg of body weight) + CAP (5 mg/kg of body weight) treatment sc and had water, 0.3 M NaCl and food removed from the home cage. Forty-five minutes later, rats received bilateral injections of moxonidine (0.5 nmol/0.2 μl) or vehicle (0.2 μl) into the LPBN. Fifteen minutes after the LPBN injections, burettes (0.1 ml subdivisions) with water and 0.3 M NaCl were available in the rat's home cage, and the rats were allowed to ingest both fluids continuously for 60 min, except for a few minutes at 15, 30 and 60 min after being given free access to both fluids. During each of these three brief periods, the rats were given a taste reactivity test. During each test the rat was removed from the home cage and placed in a taste reactivity chamber. The IO cannula of the rat was connected to a stimulus delivery tube, consisting of PE 50 tubing attached to an infusion pump and 0.3 M NaCl was infused into the mouth of the animal at a constant rate (1.0 ml/min) for 1 min, while the behavior was videotaped. At the end of each taste reactivity test, until all three tests were completed, the rat was placed back into its home cage, where water and 0.3 M NaCl were available, and the rat was allowed to drink until the next taste reactivity test. Water and 0.3 M NaCl ingested was also measured at 15, 30 and 60 min after starting the access to these fluids.
The rats received 2 tests. In each test, all rats received FURO+CAP (sc) and were then divided into two groups. One group received LPBN vehicle injections and the other LPBN moxonidine injections. The order of the tests was counterbalanced so that all animals received all treatments.
Video recording and analysis of taste reactivity
For all protocols described above, the behavior of each rat was videotaped during testing via a mirror mounted beneath the transparent floor of the test chamber. The recorded image was enlarged so the face and mouth of the rat filled the entire screen.
The behavior of each rat was scored for the occurrence of ingestive, rejection (aversive), and "neutral" taste reactivity components (see [35] for a description and discussion of taste reactivity analysis components and classification). Ingestive actions were characterized by paw licking; lateral tongue protrusions, non-rhythmic protrusions past the lip followed by forward extension; and tongue protrusions, rhythmic tongue protrusions along the midline. Neutral components were rhythmic mouth movements at the same or lower frequency as rhythmic tongue protrusions; and passive dripping, the passive leaking of fluid from the mouth. Rejection behaviors were gapes, large openings of the mandible and retraction of the lower lips; chin rubbing, bringing the mouth in direct contact with the floor and projecting the body forward; face washing, either a single wipe over the face with the paws or a bout of several wipes; forelimb flails, shaking of the forelimb; head shaking; paw treading, planting of the limbs on the floor and alternating forceful strikes forward and backward; and rapid locomotion around the chamber. This taste reactivity analysis components and classification has been previously used [53, 54] .
The behaviors were counted each time they occurred as a single event and were considered as discrete events in accordance with previous studies [36, 55] . Videotapes were scored in a slow motion analysis at l/30 to 1/l0 normal speed. The means for ingestive, rejection or neutral score were computed for each group. The ingestive and rejection scores were independently analyzed, since they represent phenomenological different categories of behavior.
Histology
At the end of the tests, the animals received bilateral injections of 2% Evans blue solution (0.2 μl) into the LPBN. They were deeply anesthetized with sodium thiopental (80 mg/kg) and perfused transcardially with 0.9% NaCl followed by 10% formalin. The brains were removed, fixed in 10% formalin, frozen, cut in 50-μm sections, stained with cresyl violet, and analyzed by light microscopy to confirm the injection sites in the LPBN.
Statistical analysis
The results are reported as means ± SEM. One-way analysis of variance (ANOVA) or two-way repeated-measures ANOVA (using treatment and time as factors), followed by Student Newman Keuls tests were used for comparisons of the results from experiments 1 and 2, respectively. Differences were considered significant at P b 0.05. (Fig. 1) . Bilateral injections of moxonidine (0.5 nmol/0.2 μl) into the LPBN did not change these responses in rats with no access to water and 0.3 M NaCl (Fig. 1). (Fig. 2) .
Experiment 2 -
In rats treated with FURO + CAP sc, moxonidine injected into the LPBN enhanced ingestive reactions at 30 and 60 min after free access to water and 0.3 M NaCl intake [F(1,24) = 13.2; p b 0.05] (Fig. 3A) , and decreased rejection responses at 15, 30 and 60 min after free access to water and 0.3 M NaCl intake [F(1,24) = 20.2; p b 0.05] (Fig. 3B) .
Most of the LPBN injections were centered in the central lateral and dorsal lateral portions of the LPBN (Fig. 4) . Injections also reached the ventral lateral and external lateral portions of the LPBN, and in some rats the caudal parts of the Kölliker-Fuse nucleus. The LPBN injection sites in the present study were similar to those of previous studies that showed the effects of moxonidine on NaCl and water intake [24, 33, 38, 39] .
Discussion
Both LPBN vehicle and LPBN moxonidine treated animals showed enhanced ingestive responses and decreased rejection responses after FURO + CAP treatment before the access to water and NaCl solution. As compared to LPBN vehicle injections, LPBN moxonidine treatment did not affect either ingestive responses or rejection responses in sodium and water depleted rats before the rats consumed any water or 0.3 M NaCl. However, in comparison to LPBN treated vehicle controls, LPBN moxonidine treated rats continued to show enhanced ingestive reactions and reduced rejection responses even after consuming large volumes of 0.3 M NaCl and water. In other words, LPBN moxonidine treatment appears to block the satiation related declines in ingestive responses or increase in rejection responses that normally occur over the course of 0.3 M NaCl and water consumption.
The increase in ingestive and the decrease in rejection reactions to 0.3 M NaCl in FURO + CAP treated rats is consistent with previous results demonstrating that animals with experimentally-induced salt appetite show enhanced ingestive and reduced rejection oro-facial and body behaviors [40, 41] . In these previous experiments where sodium depletion was induced by furosemide followed by 18 to 24 h of restricted dietary sodium, rats showed comparable increased ingestive and decreased rejection responding to IO hypertonic NaCl solution [40, 41] . In the present studies Experiment 1 showed that FURO + CAP treatment, which induces a rapid onset of sodium appetite, elicits increased ingestive behaviors and decreased rejection reactions to IO hypertonic NaCl and that this occurred regardless of whether animals received LPBN vehicle or moxonidine treatment.
Interestingly the results from experiment 1 indicated that LPBN moxonidine treatment failed to enhance ingestive behaviors or decrease rejection responses to IO 0.3 M NaCl beyond those changes seen in LPBN vehicle treated rats. In light of this outcome, we considered that this outcome might reflect a ceiling effect for ingestive responses and/or a floor effect for rejection responses. Therefore, we conducted a second experiment to test taste reactivity to IO 0.3 M NaCl in FURO + CAP treated rats after fixed periods of 0.3 M NaCl and water consumption. In the second experiment rats with LPBN vehicle treatment showed a progressive reduction in ingestive responses and an increase in rejection behaviors over the course of a 1 h test period. In contrast rats with LPBN moxonidine injections maintained a high level of ingestive responses and a low level of rejection reactions to 0.3 M NaCl throughout the entire course of the 60 min test period of free access to water and sodium. In of 0.3 M NaCl and water. These results suggest that LPBN moxonidine possibly reduces some type of inhibitory signals produced as a consequence of the ingestion of NaCl and water. An obvious consequence of blocking such inhibitory mechanisms would be to increase hypertonic NaCl intake in free access tests (i.e., to produce an enhanced salt appetite, as defined by increased hypertonic NaCl solution ingestion). Of course rats treated with FURO + CAP combined with LPBN moxonidine injections, stop the ingestion of hypertonic 0.3 M NaCl eventually, but this is likely to be the result of either a reduction of the action of moxonidine in the LPBN or due to stronger inhibition generated by the large quantity of NaCl and water ingested. Previous studies have found that visceral inhibitory feedback affects NaCl intake in rats [56] [57] [58] [59] [60] . For example, Krause and colleagues [57] demonstrated the importance of post-ingestive signals for the satiation of salt appetite and thirst in rats treated with FURO and instrumented with gastric fistulas to allow sham drinking. These investigators found that when the fistulas were open, saline and water intakes were significantly increased as compared to that of closed fistula controls. In a similar vein, Flynn et al. [58] have found that the increased intake of hypertonic NaCl observed in spontaneously hypertensive rats (SHR) in comparison to normotensive Wistar Kyoto (WKY) rats is associated with a decrease in the decline in lick rate over the course of saline access in the SHR as compared to WKY rats. These investigators suggested that the reduced decline in lick rate evidenced by SHR may be because this strain is less responsive to ingestion-contingent inhibitory feedback [58] .
Evidence indicates that interactions between taste input and inhibitory gastrointestinal, osmotic and vascular (e.g., arterial and low pressure baroreceptor) signals may act to limit excessive salt and water consumption. Information generated in the periphery is likely to influence activity at one or more central nervous system (CNS) sites where input from gustatory and various visceral sensory systems converge. The parabrachial nucleus is potentially one of these places.
Sodium taste information arrives in the CNS through the facial nerve (VII) that innervates the anterior tongue [42] . Fibers from the chorda tympani branch of the facial nerve terminate in the rostral portion of the nucleus of the solitary tract (rNTS). In turn, the rNTS sends ascending projections to the PBN. From the PBN, signals ascend to a thalamic relay, the parvocellular ventral posteromedial thalamic nucleus (VPMpc), [18, 36, 43] . Lesions placed in the NTS, PBN, or VPMpc disrupt the shift in taste reactivity observed in intact animals after sodium deficiency. However, only lesions in the NTS and PBN block increases in home-cage intake observed after intact animals were made sodium deficient [36] . Flynn and colleagues (36) showed that the PBN, the second synaptic relay of the ascending sodium taste information in rats, is also important for the taste reactivity to sodium in states of sodium deficit.
As sodium is consumed, neural and humoral post-ingestive signals from the gut and blood are detected by neurons in the caudal NTS and AP (see [44] for review). Viscerosensory afferent fibers in the vagus nerve are stimulated by gut distention (proportional to the volume of ingested fluid), by luminal hyperosmolarity (due to the hypertonicity of NaCl), and probably also by sodium-specific sensors within the portal vasculature as sodium is absorbed [45] . These activated vagal afferents stimulate neurons in the NTS as well as cells in the AP, some of which can directly monitor humoral variables such as plasma osmolarity.
The region of AP/mNTS also receives afferent projections from volume receptors (arterial baroreceptors and cardiopulmonary receptors), and these receptors can influence the ingestion of water and sodium [22, 23, 46, 47] . Activation of superior vena cava-right atrial junction receptors has been shown to attenuate isoproterenolinduced water intake in intact rats, and this inhibition is abolished by electrolytic lesions of the LPBN [48] . These findings support the hypothesis that the LPBN is involved in the inhibition of drinking mediated by volume receptor stimulation. Many neurons in the caudal or medial NTS and AP project to nuclei within the LPBN [13] . In turn, neurons in these LPBN nuclei transmit this information to a variety of limbic and hypothalamic targets in the forebrain [49, 50] , providing negative feedback signals that inhibit ingestive behaviors [7, 10, 22, 23, 33, 38, 51, 52] . In summary, the present results demonstrate that moxonidine injections into the LPBN change the pattern of taste reactivity to 0.3 M NaCl by maintaining ingestive reactions, and reducing rejection responses after free access to water and 0.3 M NaCl intake. Therefore, the present results suggest that LPBN moxonidine injections reduce inhibitory signals activated as a consequence of the ingestion of hypertonic NaCl solution and water.
